In the US pharmaceutical industry, there were 210 M&A deals announced in Q4 2023, worth a total value of $64.6bn, according to GlobalData’s Deals Database. The $14bn acquisition of Karuna Therapeutics by Bristol-Myers Squibb was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, M&A activity in the US increased by 287% in Q4 2023 compared with the previous quarter’s total of $16.7bn and rose by 289% as compared to Q4 2022. Related deal volume increased by 12% in Q4 2023 versus the previous quarter and was 4% higher than in Q4 2022.
The top-ranked financial advisors supporting these M&A deals in the US in Q4 2023 were Centerview Partners; SVB Financial Group; Goldman Sachs Group with 20, 13, 10 deals respectively.
The top-ranked legal advisorss supporting these M&A deals in the US Q4 2023 were Goodwin Procter; Gibson, Dunn & Crutcher; Kirkland & Ellis with 24, 23, 23 deals respectively.
See Also:
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in 2023 – Thematic Intelligence, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.